^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    evexomostat (SDX-7320)

    i
    Other names: SDX-7320, SDX 7320, SDX7320
    Associations

    News

    Trials
    Company:
    SynDevRx
    Drug class:
    MetAP2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2. (PubMed, Cancer Res Commun)
    Evexomostat (SDX-7320) was well-tolerated with prolonged stable disease and metastatic control in an open-label, Phase I safety study. Improvements were observed in angiogenic and metabolic biomarkers.
    P1 data • Journal
    |
    FGF2 (Fibroblast Growth Factor 2) • VEGFC (Vascular Endothelial Growth Factor C) • LEP (Leptin)
    |
    evexomostat (SDX-7320)
    almost2years
    Amelia-1: Evexomostat Plus Alpelisib and Fulvestrant in Women With the PIK3CA Mutation With HR+/Her2- Breast Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, SynDevRx, Inc. | Phase classification: P1b/2 --> P1/2
    Phase classification • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 negative • PIK3CA mutation
    |
    Piqray (alpelisib) • fulvestrant • evexomostat (SDX-7320)
    over3years
    Amelia-1: Evexomostat Plus Alpelisib and Fulvestrant in Postmenopausal Women at Risk for Hyperglycemia With Breast Cancer (clinicaltrials.gov)
    P1b/2, N=52, Recruiting, SynDevRx, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGF2 (Fibroblast Growth Factor 2) • VEGFC (Vascular Endothelial Growth Factor C) • LEP (Leptin)
    |
    HER-2 negative • PIK3CA mutation
    |
    Piqray (alpelisib) • fulvestrant • evexomostat (SDX-7320)
    over3years
    ARETHA: A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer (clinicaltrials.gov)
    P2, N=55, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Halaven (eribulin mesylate) • evexomostat (SDX-7320)
    almost5years
    [VIRTUAL] SDX-7320, a novel inhibitor of methionine aminopeptidase 2 (MetAP2), inhibits MCF-7 tumor growth in combination with palbociclib (Ibrance®) (AACR 2021)
    In addition SDX-7320 synergized with the PI3Kα inhibitor alpelisib (Piqray®) to block the growth of ER+/Her2- MCF-7 xenografts. Intracellular pathways and proteins linked to emergence of resistance to palbociclib include cell cycle (cyclin E1), growth factor and hormone signaling (Akt, ERα) and autophagy (LC3B). The protein changes observed (representative of these pathways) suggest that combining SDX-7320 with palbociclib (Ibrance®) may extend the period of progression-free survival in patients with ER+/Her2- breast cancer relative to treatment with palbociclib (Ibrance®) alone.
    Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCNE1 (Cyclin E1) • CDK2 (Cyclin-dependent kinase 2)
    |
    Ibrance (palbociclib) • Piqray (alpelisib) • evexomostat (SDX-7320)